S100A1 and heart failure: Studies have shown that AAV9 enables broad myocardial distribution following intravenous or intracoronary injection and has demonstrated superior performance in delivering therapeutic genes such as SERCA2a, cBIN1, MYBPC3, and S100A1 in various models of heart failure and inherited cardiomyopathies (38–40, 42, 85).